Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Tandem Diabetes Care Inc (TNDM)

Healthcare Medical Devices
19.50 $
+2.6% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Tandem Diabetes Care Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Trading Day

Previous Close
19.00$
Open
19.10$
Day High
19.70$
Day Low
18.60$
Volume
1,829,332shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
10.10 $ 28.30 $
08/11/2025 02/23/2026

Current price 19.50 $ — 52% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
1.3$B
Shares Outstanding
69Mio.
Float
91.8%
Beta
1.6

Performance

Perf. 1M
-5.30%
Perf. 3M
-24.60%
Perf. 6M
-29.60%
YTD Performance (%)
-34.40%
52-Week-High Distance
-46.9%
Perf. 1Y
25.16%
Perf. 3Y
-44.16%
Perf. 5Y
-82.06%
Perf. 10Y
-70.59%
Perf. Since Inception
-89.88%

Technical Indicators

MA 38 Days
16.40$
MA 50 Days
16.50$
MA 200 Days
19.00$
RSI (14)
68.5
Volatility 30 Days
55.3%
Volatility 250 Days
78.0%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
126.6
PEG
P/B
P/S
1.3
EV/EBITDA
345.7
Price/FCF

Profitability

Gross Margin
54.9%
EBIT Margin
Net Margin
-9.2%
Return on Equity
-65.7%
Return on Assets
-3.7%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
Altman Z″
2.90
Piotroski
5 out of 9

Growth

Sales Growth Last Quarter
5.50%
EPS Growth Last Quarter
-37.00%
Sales Growth (Year)
7.93%
Forward Sales Growth
12.34%
Forward EPS Growth
110.00%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
1
RS Rating
11
EPS Rating
18
Piotroski
5 out of 9
Fundamental Rating
C (50 out of 100)
Altman Z″
2.90

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Analysts & Price Target

Current Price 19.50 $
Price Target (average) 28.88 $

The price target sits 48.1% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

6. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-0.34 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 282.6 $M Q4 2025: Q1 · 234.4 $M Q1 2025: Q2 · 240.7 $M Q2 2025: Q3 · 249.3 $M Q3 2025: Q4 · 290.4 $M Q4 2026: Q1 · 247.2 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 0.01 283 43.60 0.30 11 8
2025: Q1 -1.97 234 22.30 -55.70 -18 -21
2025: Q2 -0.78 241 8.50 -21.80 -10 -16
2025: Q3 -0.31 249 -31.40 -8.50 8 4
2025: Q4 -0.01 -175.90 290 2.70 -0.20 10 3
2026: Q1 -0.30 247 5.50 -8.20 11 5
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Tandem Diabetes Care, Inc. entwirft, entwickelt und vermarktet Technologielösungen für Menschen mit Diabetes in den USA und international.

CEO Insider Trades (12 Mo.)buying own stock
Employees2,500
HeadquartersSan Diego, CA
Websitetandemdiabetes.com
IPO Date14. Nov 2013

Management

Management
Name Title Birth Year
John F. Sheridan President, CEO & Director 1955
Leigh A. Vosseller Executive VP, CFO & Treasurer 1973
Shannon M. Hansen J.D. Executive VP, Chief Legal, Privacy & Compliance Officer and Secretary 1966
Elizabeth Anne Gasser Executive VP and Chief Strategy & Product Officer 1976
Jean-Claude E. Kyrillos Executive VP & COO 1964
Rick A. Carpenter Executive VP & CTO 1963
Susan M. Morrison Executive VP & Chief Administrative Officer 1979
Tom Fox Executive VP & Chief Human Resources Officer
Jordan Pinsker M.D. Chief Medical Officer

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
15. Jul 2026 Kyrillos Jean-Claude EVP & Chief Operating Officer Other 1,926 15.28 29,429
15. Jul 2026 Kyrillos Jean-Claude EVP & Chief Operating Officer Other 3,636 0.00

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?